Nordic Issuing

Ongoing case

Eurocine Vaccines AB

Back to all cases

Eurocine Vaccines AB

14 Mar - 28 Mar 2022Warrant exercise

Eurocine Vaccines develops vaccines for human and veterinary use. The company identifies, evaluates, selects and agrees on vaccine antigen for further development within its own vaccine portfolio based on a balance of several factors such as medical need, market potential, patent protection and technical feasibility. The vaccines are developed based on the company’s extensive knowledge and experience in the vaccine area and the technology platform Endocine ™.

Read more on the company's website

The offer in summary

Subscription period: 14 March 2022 - 28 March 2022

Price per share: SEK 1.41

Trading with warrant: Until 24 March 2022

The offer:

Payment day: 28 March 2022

Marketplace: Spotlight Stockmarket

Financial advisor: Sedermera Corporate Finance




Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.